

## **AMENDMENTS TO THE CLAIMS**

This listing of claims replaces all prior versions and listings of claims.

1. (previously presented) The use of a medicament containing alprostadil for angioneogenesis.
2. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is employed within the framework of the treatment of chronic heart failure and/or cardiomyopathy.
3. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is employed within the framework of a neovascularization.
4. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is used to reduce the degree of fibrosis.
5. (previously presented) The use as claimed in claim 1 wherein the angioneogenesis is used for regression of hypertrophy.
6. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis for revitalization of dead areas of the heart, especially after a myocardial infarction.
7. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is used for the treatment of advanced peripheral arterial occlusive diseases.
8. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is used for the treatment of diabetic angiopathy.
9. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is used for the treatment of systemic lung disorders, especially pulmonary fibrosis.
10. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is used for the treatment of acute or chronic renal failure and glomerulonephritis.

11. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is used for the treatment of acute or chronic hepatic failure.

12. (previously presented) The use as claimed in claim 1, wherein the angioneogenesis is used for the treatment of cerebral infarction.

13. (previously presented) A medicament for angioneogenesis comprising alprostadil, wherein the angioneogenesis is used in a treatment selected from the group consisting of (a) treatment of chronic heart failure and/or cardiomyopathy, (b) treatment involving neovascularization, (c) treatment to reduce fibrosis, (d) treatment for regression of hypertrophy, (e) treatment to revitalize dead areas of the heart, (f) treatment of advanced peripheral arterial occlusive diseases, (g) treatment of diabetic angiopathy; (h) treatment of systematic lung disorders; (i) treatment of renal failure; (k) treatment of glomerulonephritis; (j) treatment of hepatic failure, and (l) treatment of cerebral infarction.